




## ARIA Summit: *Cardiovascular and Stroke Considerations for $\beta$ -Amyloid Immunotherapy in Alzheimer Disease*

### Executive Summary



Summit Co-Chairs Dr. Costantino Iadecola and Dr. Steven Greenberg with American Heart Association Chief Clinical Science Officer for Brain Health and Stroke Dr. Mitchell Elkind at the event in Chicago on July 16, 2025.

Nearly one million people over age 65 are diagnosed with Alzheimer's disease (AD) each year in the U.S.<sup>1</sup> New anti-amyloid therapies (AAT) for the treatment of patients with early AD, which slow the progression of the disease, have become available in the last two years. However, these therapies come with potentially serious side effects, most notably amyloid-related imaging abnormalities (ARIA). Given that many patients with AD are likely to have comorbid cardiovascular (CV) risk factors or conditions, the American Heart Association convened a summit in July 2025 to develop additional guidance for health professionals caring for these patients.

In preparation for the summit, the Association convened a multidisciplinary group of experts across vascular and behavioral neurology, cardiology, radiology, emergency medicine, nursing and other specialties. These experts were divided into eight work groups to evaluate the current evidence related to AAT use in patients with CV risk factors and conditions and to develop consensus-based guidance for clinicians. The eight work groups focused on the following topics:

- Vascular considerations for patient selection when implementing immunotherapy;
- Communicating with patients and families;
- Primary care professionals in management of patients with CV comorbidities;
- Emergency evaluation and treatment of patients on AAT with acute neurological symptoms;
- Imaging in AAT monitoring and diagnosis and treatment of ARIA;
- Team-based approach to CV and other systemic conditions;
- Systems of care; and
- Future research and data collection needs.

A report summarizing the deliberations of the work groups and summit and putting forward considerations for caring for patients with AD who are at risk for cerebrovascular disease and ARIA has been developed and submitted for publication. The full report will be made available upon publication at [professional.heart.org/ARIAsummit](https://professional.heart.org/ARIAsummit).

---

<sup>1</sup> Alzheimer's Association. 2025 Alzheimer's Disease Facts and Figures. Accessed online at: <https://www.alz.org/getmedia/ef8f48f9-ad36-48ea-87f9-b74034635c1e/alzheimers-facts-and-figures.pdf> on Dec. 3, 2025.